Compare IRMD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | WVE |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | Singapore |
| Employees | 166 | 317 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2014 | 2015 |
| Metric | IRMD | WVE |
|---|---|---|
| Price | $92.02 | $6.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | ★ $116.00 | $29.81 |
| AVG Volume (30 Days) | 109.3K | ★ 2.2M |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $83,814,000.00 | $3,704,000.00 |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $11.31 | $85.67 |
| P/E Ratio | $106.06 | ★ N/A |
| Revenue Growth | 14.43 | ★ 149.43 |
| 52 Week Low | $67.84 | $5.02 |
| 52 Week High | $107.90 | $21.73 |
| Indicator | IRMD | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 53.05 |
| Support Level | $90.96 | $5.49 |
| Resistance Level | $97.63 | $6.21 |
| Average True Range (ATR) | 3.10 | 0.25 |
| MACD | -0.50 | 0.03 |
| Stochastic Oscillator | 18.99 | 83.54 |
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.